CN107884574A - Chlamydia trachomatis detection reagent card, kit and application thereof - Google Patents
Chlamydia trachomatis detection reagent card, kit and application thereof Download PDFInfo
- Publication number
- CN107884574A CN107884574A CN201711057573.8A CN201711057573A CN107884574A CN 107884574 A CN107884574 A CN 107884574A CN 201711057573 A CN201711057573 A CN 201711057573A CN 107884574 A CN107884574 A CN 107884574A
- Authority
- CN
- China
- Prior art keywords
- chlamydia trachomatis
- line
- antibody
- test
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940038705 chlamydia trachomatis Drugs 0.000 title claims abstract description 166
- 241000606153 Chlamydia trachomatis Species 0.000 title claims abstract description 117
- 238000001514 detection method Methods 0.000 title claims abstract description 79
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 59
- 238000012360 testing method Methods 0.000 claims abstract description 106
- 239000000427 antigen Substances 0.000 claims abstract description 94
- 102000036639 antigens Human genes 0.000 claims abstract description 94
- 108091007433 antigens Proteins 0.000 claims abstract description 94
- 239000004816 latex Substances 0.000 claims abstract description 94
- 229920000126 latex Polymers 0.000 claims abstract description 94
- 239000002245 particle Substances 0.000 claims abstract description 55
- 239000000020 Nitrocellulose Substances 0.000 claims abstract description 35
- 229920001220 nitrocellulos Polymers 0.000 claims abstract description 35
- 238000000034 method Methods 0.000 claims abstract description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000000243 solution Substances 0.000 claims description 72
- 239000012528 membrane Substances 0.000 claims description 55
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 16
- 229920002678 cellulose Polymers 0.000 claims description 15
- 239000001913 cellulose Substances 0.000 claims description 15
- 239000011521 glass Substances 0.000 claims description 15
- 238000005507 spraying Methods 0.000 claims description 14
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 12
- 239000011259 mixed solution Substances 0.000 claims description 8
- 239000004475 Arginine Substances 0.000 claims description 6
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 6
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 6
- 239000004471 Glycine Substances 0.000 claims description 6
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 6
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims description 6
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 6
- 229960001230 asparagine Drugs 0.000 claims description 6
- 235000009582 asparagine Nutrition 0.000 claims description 6
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 6
- IWZKICVEHNUQTL-UHFFFAOYSA-M potassium hydrogen phthalate Chemical compound [K+].OC(=O)C1=CC=CC=C1C([O-])=O IWZKICVEHNUQTL-UHFFFAOYSA-M 0.000 claims description 6
- 241000283707 Capra Species 0.000 claims description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 5
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 238000012412 chemical coupling Methods 0.000 claims description 4
- 238000003317 immunochromatography Methods 0.000 abstract description 3
- 239000003365 glass fiber Substances 0.000 abstract 2
- 241000606161 Chlamydia Species 0.000 abstract 1
- 239000000839 emulsion Substances 0.000 abstract 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 abstract 1
- 206010044325 trachoma Diseases 0.000 abstract 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 26
- 239000008055 phosphate buffer solution Substances 0.000 description 23
- 239000004793 Polystyrene Substances 0.000 description 8
- 229920002223 polystyrene Polymers 0.000 description 8
- 238000007865 diluting Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000011088 calibration curve Methods 0.000 description 5
- 238000001035 drying Methods 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 230000031700 light absorption Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000009210 therapy by ultrasound Methods 0.000 description 4
- 101710105759 Major outer membrane porin Proteins 0.000 description 3
- 101710164702 Major outer membrane protein Proteins 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 108010077544 Chromatin Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000011140 membrane chromatography Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention relates to emulsion technique immunochromatography field, and in particular to a kind of chlamydia trachomatis detection reagent card, including sample application pad, glass fibre element film, nitrocellulose filter and the water suction pad being arranged in order；Wherein, latex particle the first Against Chlamydia Trachomatis antibody and latex particle test antigen are contained on the glass fibre element film；The first p-wire, the second p-wire and control line are disposed with the nitrocellulose filter；First p-wire has been coated with the second Against Chlamydia Trachomatis antibody；Second p-wire has been coated with trachoma chlamydia antigen；The control line has been coated with the antibody of the test antigen.
Description
Technical Field
The invention relates to the field of latex immunochromatography, in particular to a chlamydia trachomatis detection reagent card, a kit and application thereof.
Background
All immunodiagnostic reagents, either qualitative or quantitative, are based on the principle of immunoreaction, i.e., antigen and antibody are specifically combined under certain conditions to produce antigen-antibody complex, and the antigen or antibody is labeled with tracer to finally realize the detection and analysis of reaction products.
In the prior art, an immunodiagnostic reagent card is provided with a test line, and whether a sample contains pathogen antigens or not is determined according to the color of the test line. The judgment is carried out through the color of one test line, the influence of the brightness and the color of the environment is easy to be caused, and the influence of the subjective judgment of a user is also caused, so that a larger error is generated, the accuracy of a detection result, particularly a quantitative detection result is lower, and the obstacle is brought to the diagnosis of diseases.
Disclosure of Invention
In view of the above-mentioned disadvantages of the prior art, the present invention aims to provide a chlamydia trachomatis detection reagent card, a kit and a use thereof, so as to reduce detection errors and improve the accuracy of detection results.
In a first aspect, the invention provides a reagent card for detecting chlamydia trachomatis, which comprises a sample adding gasket, a glass cellulose membrane, a nitrocellulose membrane and a water absorbing gasket which are arranged in sequence; wherein the glass cellulose membrane comprises latex particles-a first anti-chlamydia trachomatis antibody and latex particles-a test antigen; the nitrocellulose membrane is sequentially provided with a first test line, a second test line and a control line; the first test line is coated with a second anti-chlamydia trachomatis antibody; the second test line is coated with a chlamydia trachomatis antigen; the control line is coated with an antibody to the test antigen.
In one embodiment of the invention, the test antigen is rabbit IgG; the antibody of the test antigen is goat anti-rabbit IgG.
In one embodiment of the invention, the first anti-chlamydia trachomatis antibody and/or the second anti-chlamydia trachomatis antibody is a monoclonal antibody.
In one embodiment of the invention, the latex particles in the latex particle-first anti-chlamydia trachomatis antibody and the first chlamydia trachomatis antibody are linked by chemical coupling, and/or the latex particles in the latex particle-test antigen and the test antigen are linked by chemical coupling.
In a second aspect, the present invention provides a method for preparing a reagent card for detecting chlamydia trachomatis according to the first aspect, comprising the following steps: 1) spraying a mixed solution of latex particles, a first anti-chlamydia trachomatis antibody and latex particles, and a test antigen on a glass cellulose membrane; 2) carrying out first pretreatment on a nitrocellulose membrane corresponding to a T1 line to be spotted by using a first pretreatment solution, and spotting a second anti-chlamydia trachomatis antibody solution on the nitrocellulose membrane subjected to the first pretreatment; 3) performing second pretreatment on the nitrocellulose membrane corresponding to the T2 line to be spotted by using a second pretreatment solution, and spotting a chlamydia trachomatis antigen solution on the nitrocellulose membrane subjected to the second pretreatment; 4) and spraying an antibody solution of the test antigen on the nitrocellulose membrane at a preset position.
In one embodiment of the present invention, the first pretreatment solution is an aqueous solution containing 1.5-2g/L arginine, 1.2-1.5g/L potassium hydrogen phthalate, 0.3-0.5g/L sodium hydroxide, and 2-2.5g/L citric acid.
In one embodiment of the invention, the second pretreatment solution is an aqueous solution containing 2-2.5g/L of asparagine, 0.5-0.7g/L of disodium hydrogen phosphate, 3-4g/L of rhamnose and 3-3.5g/L of glycine.
In a third aspect, the invention provides a use of the chlamydia trachomatis detection reagent card of the first aspect in preparing a chlamydia trachomatis detection kit.
In one embodiment of the invention, the use is in particular to detect a chlamydia trachomatis antigen in a sample by using the chlamydia trachomatis detection kit.
In one embodiment of the present invention, the use specifically includes: the ratio of the value of the first test line to the value of the second test line and/or the ratio of the value of the first test line to the value of the control line is used for obtaining the content of the chlamydia trachomatis; wherein the value of the first test line is obtained from the color brightness exhibited by the latex particles enriched in the first test line, the value of the second test line is obtained from the color brightness exhibited by the latex particles enriched in the second test line, and the value of the control line is obtained from the color brightness exhibited by the latex particles enriched in the control line.
In one embodiment of the present invention, the color is red.
In a fourth aspect, the invention provides a chlamydia trachomatis detection kit, which comprises the chlamydia trachomatis detection reagent card of the first aspect.
Compared with the prior art, the invention has the following beneficial effects: the ratio of the two test lines or the ratio of the test line to the control line is adopted to determine the amount of the chlamydia trachomatis, so that the error can be effectively reduced, and the accuracy of a detection result, particularly a quantitative detection result, is improved; and avoids the mutual interference between the control system and the test system; and the control system can adopt an antigen-antibody reactant which does not interfere with the test system, so that the mutual interference between the control system and the test system is avoided, and the accuracy and precision of detection are improved.
Drawings
Fig. 1 is a schematic structural diagram of a chlamydia trachomatis detection reagent card provided by an embodiment of the present invention.
Detailed Description
Before the present embodiments are further described, it is to be understood that the scope of the invention is not limited to the particular embodiments described below; it is also to be understood that the terminology used in the examples is for the purpose of describing particular embodiments, and is not intended to limit the scope of the present invention; in the description and claims of the present application, the singular forms "a", "an" and "the" include plural referents unless the context clearly dictates otherwise.
When numerical ranges are given in the examples, it is understood that both endpoints of each of the numerical ranges and any value therebetween can be selected unless the invention otherwise indicated. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In addition to the specific methods, devices, and materials used in the examples, any methods, devices, and materials similar or equivalent to those described in the examples may be used in the practice of the invention in addition to the specific methods, devices, and materials used in the examples, in keeping with the knowledge of one skilled in the art and with the description of the invention.
Unless otherwise indicated, the experimental methods, detection methods, and preparation methods disclosed herein all employ techniques conventional in the art of molecular biology, biochemistry, chromatin structure and analysis, analytical chemistry, cell culture, recombinant DNA technology, and related arts. These techniques are well described in the literature, and may be found in particular in the study of the MOLECULAR CLONING, Sambrook et al: a LABORATORY MANUAL, Second edition, Cold Spring harbor LABORATORY Press, 1989and Third edition, 2001; ausubel et al, Current PROTOCOLS Inmolecular BIOLOGY, John Wiley & Sons, New York, 1987and periodic updates; the series METHODS IN ENZYMOLOGY, Academic Press, San Diego; wolffe, CHROMATINSTRUCUTURE AND FUNCTION, Third edition, Academic Press, San Diego, 1998; (iii) Methods Inenzymolygy, Vol.304, Chromatin (P.M. Wassarman and A.P.Wolffe, eds.), academic Press, San Diego, 1999; and METHODS IN MOLECULAR BIOLOGY, Vol.119, chromatography protocols (P.B.Becker, ed.) Humana Press, Totowa, 1999, etc.
The embodiment of the invention provides a chlamydia trachomatis detection reagent card, and the structure of the reagent card is shown in figure 1. On the reagent card, a sample adding gasket, a glass cellulose membrane, a nitrocellulose membrane and a water absorption gasket are arranged in sequence.
The glass cellulose membrane contains latex particles-a first anti-chlamydia trachomatis antibody and latex particles-a test antigen. The latex particles have a specific color and may be colored latex particles. The latex particle-first anti-chlamydia trachomatis antibody and latex particle-test antigen may be chromatographed onto the nitrocellulose membrane. The nitrocellulose membrane is provided with a T1 line, a T2 line and a C line in sequence. The T1 line and the T2 line are test lines, and the C line is a control line. T1 line coated with a second anti-chlamydia trachomatis antibody; t2 line coated with chlamydia trachomatis antigen; the C-line is coated with antibodies to the test antigen.
The latex particle-first anti-chlamydia trachomatis antibody refers to a latex particle labeled first anti-chlamydia trachomatis antibody.
The latex particle-test antigen refers to a latex particle-labeled test antigen.
The test antigen refers to an antigen other than a chlamydia trachomatis antigen, such as IgG.
The latex particle marked test antigen on the sample adding pad and the antibody of the test antigen coated by the C line are used for verifying whether the detection reagent card fails.
The chlamydia trachomatis detection reagent card provided by the embodiment of the invention adopts the latex immunochromatography technology and the principle of a double-antibody sandwich method. When the detection is carried out, if the chlamydia trachomatis exists in the sample, the chlamydia trachomatis firstly combined with the first anti-chlamydia trachomatis antibody marked by the latex particles to form a latex immune complex, when the latex immune complex is chromatographed to a T1 line, the latex immune complex is captured by the second anti-chlamydia trachomatis antibody coated on a T1 line in advance, the latex immune complex is enriched at a T1 line, the higher the concentration of the chlamydia trachomatis in the sample, the more the latex immune complex is enriched on the T1 line, and the darker the color of the T1 line is; if the sample contains less Chlamydia trachomatis than the latex particle-first anti-Chlamydia trachomatis antibody, the remaining latex particle-labeled first anti-Chlamydia trachomatis antibody will be chromatographed to line T2, the lower the concentration of Chlamydia trachomatis in the sample, the more latex particles are enriched on line T2, and the darker the color of line T2; the detection area or linear interval of the reagent card is widened.
The detection result of the Chlamydia trachomatis detection reagent card provided by the embodiment of the invention is characterized by the ratio of T1/T2 or the ratio of T1/C. The T1 value, T2 value and C value are expressed in terms of the color brightness of latex particles enriched on the T1 line, the color brightness of latex particles enriched on the T2 line and the color brightness of latex particles enriched on the C line, respectively. The color brightness can be read by an instrument matched with the reagent card; the user may also take a picture of the reagent card and the color intensity of each line on the picture is read by the computer.
The detection of the chlamydia trachomatis by using the reagent card for detecting chlamydia trachomatis provided by the embodiment of the invention can have the following situations.
(1) When the sample contains chlamydia trachomatis from the absence to the presence, the immune complex formed by chlamydia trachomatis and the first chlamydia trachomatis antigen antibody is more and more, the free first chlamydia trachomatis antigen antibody is less and less, therefore, the latex particles captured by the T1 line are more and more, and the latex particles captured by the T2 line are less and less. The T1 value is gradually increased from none, the T2 value is gradually increased from strong to weak, and the C value is unchanged, then: the T1/T2 is gradually increased from a minimum value, and the T1/C is gradually increased from a minimum value.
(2) When the Chlamydia trachomatis in the equivalent zone in the sample, the immune complex formed by the Chlamydia trachomatis and the first Chlamydia trachomatis antigen antibody is the most, the free first Chlamydia trachomatis antigen antibody is the least, the T1 value is the largest, the T2 value is the smallest, and the C value is unchanged. Then: T1/T2 is big from big to big, and T1/C is gradually strengthened.
Therefore, the content of Chlamydia trachomatis in the sample is obtained from the ratio of T1/T2 or the ratio of T1/C. In practical applications, a calibration curve of the T1/T2 or T1/C ratio can be fitted with a standard, and the content of Chlamydia trachomatis in the sample can be calculated according to the standard curve.
While the prior art reagent card for detecting chlamydia trachomatis is coated with only one test line, the specific situation in the above case is as follows.
(1) When chlamydia trachomatis is present in the sample from scratch: t1 becomes stronger from none to gradually and quickly approaches a constant;
(2) when the Chlamydia trachomatis in the sample is within the equivalence band, then the T1 constant.
The amount of the chlamydia trachomatis is determined by only one test line, so that the error is large, and the accuracy is low particularly for the quantitative detection of the chlamydia trachomatis.
The chlamydia trachomatis detection reagent card provided by the embodiment of the invention adopts the ratio of the two test lines or the ratio of the test line to the control line to determine the amount of the chlamydia trachomatis, can effectively reduce errors, and can be suitable for quantitative determination of the chlamydia trachomatis.
The test antigen is in particular an antigen different from chlamydia trachomatis. If the reagent card is specifically used for detecting human chlamydia trachomatis, the test antigen is a non-human antigen, so that the human sample cannot be interfered. The test antigen and test antigen antibody do not cross-interfere with the antigen-antibody system of the test line system. The system methodology error is controlled, and the detection accuracy and precision are improved.
In one example, the test antigen is rabbit IgG; the antibody of the test antigen is goat anti-rabbit IgG.
In one example, the first anti-chlamydia trachomatis antibody and/or the second anti-chlamydia trachomatis antibody is a monoclonal antibody. Compared with polyclonal antibody, the monoclonal antibody expressed by purified genetic engineering has better specificity and targeting property and more stable quality. Further, the first anti-chlamydia trachomatis antibody and the second anti-chlamydia trachomatis antibody are different monoclonal antibodies, for example, the first anti-chlamydia trachomatis antibody may be a MOMP monoclonal antibody of Abnova (cat No. MAB8525), and the second anti-chlamydia trachomatis antibody may be a LPS monoclonal antibody of Abnova (cat No. MAB 6166).
In one example, the latex particles are red in color.
The latex particles may be polystyrene latex particles. The particle size of the polystyrene latex particles can be 290-300 nm.
In embodiments of the present invention, the latex particles are specifically antibodies that are capable of chemically coupling to the first anti-chlamydia trachomatis antibody and the test antigen, thereby making the latex particles more strongly bound to the first anti-chlamydia trachomatis antibody and the test antigen.
The latex particles may be carboxylated latex particles. For example: carboxylated polystyrene latex particles. Specifically, carboxylated polystyrene latex particles may be coupled to a first anti-chlamydia trachomatis antibody and a test antigen using a carbodiimide method. The detection reagent card provided by the embodiment of the invention determines the amount of the chlamydia trachomatis according to the ratio of the two test lines or the ratio of the test line to the control line, thereby effectively reducing the error and being suitable for quantitative determination of the chlamydia trachomatis; and the control system can adopt an antigen-antibody reactant which does not interfere with the test system, so that the mutual interference between the control system and the test system is avoided, and the accuracy and precision of detection are improved. In addition, compared with a colloidal gold reagent, the chlamydia trachomatis detection reagent card provided by the embodiment of the invention has the advantages of good sensitivity, strong specificity and the like; compared with the PCR method, the method has the advantages of convenience, rapidness and economy.
The embodiment of the invention also provides a preparation method of the chlamydia trachomatis detection reagent card, which comprises the following steps: 1) spraying a mixed solution of latex particles, a first anti-chlamydia trachomatis antibody and latex particles, and a test antigen on a glass cellulose membrane; 2) carrying out first pretreatment on a nitrocellulose membrane corresponding to a T1 line to be spotted by using a first pretreatment solution, and spotting a second anti-chlamydia trachomatis antibody solution on the nitrocellulose membrane subjected to the first pretreatment; 3) performing second pretreatment on the nitrocellulose membrane corresponding to the T2 line to be spotted by using a second pretreatment solution, and spotting a chlamydia trachomatis antigen solution on the nitrocellulose membrane subjected to the second pretreatment; 4) and spraying an antibody solution of the test antigen on the nitrocellulose membrane at a preset position.
In one example, the first pretreatment solution is an aqueous solution containing 1.5-2g/L arginine, 1.2-1.5g/L potassium hydrogen phthalate, 0.3-0.5g/L sodium hydroxide, 2-2.5g/L citric acid. In one example, the second pretreatment solution is an aqueous solution containing 2-2.5g/L asparagine, 0.5-0.7g/L disodium hydrogen phosphate, 3-4g/L rhamnose, 3-3.5g/L glycine. During preparation, the nitrocellulose membrane corresponding to the T1 line is pretreated by using the first pretreatment solution, and the nitrocellulose membrane corresponding to the T2 line is pretreated by using the second pretreatment solution, so that the detection sensitivity and accuracy of the chlamydia trachomatis detection reagent card can be remarkably improved.
The embodiment of the invention also provides the application of the chlamydia trachomatis detection reagent card in preparation of the chlamydia trachomatis detection reagent card.
In one example, the use is in particular for detecting a chlamydia trachomatis antigen in a sample using the chlamydia trachomatis detection kit.
In one example, the use specifically includes: the ratio of the value of the first test line to the value of the second test line and/or the ratio of the value of the first test line to the value of the control line is used for obtaining the content of the chlamydia trachomatis; wherein the value of the first test line is obtained from the color brightness exhibited by the latex particles enriched in the first test line, the value of the second test line is obtained from the color brightness exhibited by the latex particles enriched in the second test line, and the value of the control line is obtained from the color brightness exhibited by the latex particles enriched in the control line.
In one example, the color is red.
The embodiment of the invention also provides a chlamydia trachomatis detection kit, which comprises the chlamydia trachomatis detection reagent card.
In the following specific examples and comparative examples, the detection effect of the chlamydia trachomatis detection reagent card provided by the present invention is illustrated by using a labeling recovery method.
Example 1
11. The preparation method of the chlamydia trachomatis detection reagent card comprises the following steps:
111. preparation of a mixed solution of latex particle-first anti-chlamydia trachomatis antibody and latex particle-test antigen:
adding the required volume of the MOMP monoclonal antibody and the carboxylated red polystyrene latex particles into 0.05M PBS (phosphate buffer solution) with a preset volume, performing ultrasonic treatment, centrifuging and other operation steps to obtain a latex particle-first anti-chlamydia trachomatis antibody solution, diluting, and measuring the light absorption value of the suspension at 500nm by using a spectrophotometer to obtain the latex particle-first anti-chlamydia trachomatis antibody solution. Adding the required volume of rabbit IgG and carboxylated red polystyrene latex particles into 0.05M PBS (phosphate buffer solution) with a preset volume, performing ultrasonic treatment, centrifuging and other operation steps to obtain a latex particle-test antigen solution, diluting the latex particle-test antigen solution, and measuring the light absorption value of the suspension at 500nm by using a spectrophotometer to obtain the latex particle-test antigen solution. Mixing the prepared latex particle-first anti-chlamydia trachomatis antibody solution and the latex particle-test antigen solution, and storing at 2-8 ℃.
112. Diluting the mixed solution obtained in the step 111 by PBS (phosphate buffer solution) with the pH value of 6.8-7.2 and the concentration of 0.01-0.05M until the OD720 is 2.0-4.0, spraying the obtained solution onto a glass cellulose membrane, wherein the spraying amount is 2-5mg/ml, and drying at 35-45 ℃ to obtain the glass cellulose membrane containing latex particles, namely the first anti-chlamydia trachomatis antibody and the latex particles, namely the test antigen.
113. C, preparation of line solution: using PBS (0.01-0.05M, pH6.8-7.2) to prepare goat anti-rabbit IgG solution, wherein the final concentration of the solution is 1.0-2.0 mg/ml.
114. Preparation of T1 line solution: and (3) preparing a second anti-chlamydia trachomatis antibody solution by using PBS (phosphate buffer solution) with the pH value of 0.01-0.05M and the pH value of 6.8-7.2, wherein the LPS monoclonal antibody is used as the second anti-chlamydia trachomatis antibody, and the final concentration of the solution is 1.0-2.0 mg/ml.
115. Preparation of T2 line solution: PBS (0.01-0.05M, pH6.8-7.2) is used to prepare the Chlamydia trachomatis antigen solution, the final concentration of the solution is 1.0-2.0 mg/ml.
116. Pretreating the cellulose nitrate membrane corresponding to the T1 line to be sprayed with a first pretreatment solution, wherein the formula of the first pretreatment solution is as follows: 1.5g/L of arginine, 1.2g/L of potassium hydrogen phthalate, 0.5g/L of sodium hydroxide, 2.0g/L of citric acid, water as a solvent, and the pH value of 6.5, wherein the pretreatment comprises the following specific steps:
1161. uniformly dropwise adding 5 mu l of first pretreatment solution on a T1 line, and airing at room temperature;
1162. step 1161 is repeated twice.
117. Pretreating the cellulose nitrate membrane corresponding to the T2 line to be sprayed with a second pretreatment solution, wherein the formula of the second pretreatment solution is as follows: 2.5g/L of asparagine, 0.5g/L of disodium hydrogen phosphate, 4g/L of rhamnose, 3.5g/L of glycine, water as a solvent, and a pH value of 7.6, wherein the pretreatment comprises the following specific steps:
1171. uniformly dropwise adding 5 mu l of second pretreatment buffer solution to a T2 line, and airing at room temperature;
1172. step 1171 is repeated twice.
118. Dot spraying of a C line, a T1 line and a T2 line on the nitrocellulose membrane by using a C line solution, a T1 line solution and a T2 line solution respectively: washing a micro-protein spot membrane system by using PBS (phosphate buffer solution) with the concentration of 0.01M and the pH value of 7.2, adjusting parameters of a membrane spraying instrument, connecting an inlet pipeline and an outlet pipeline, respectively putting a C pipeline, a T1 pipeline and a T2 pipeline into solutions of a C line, a T1 line and a T2 line, adjusting the spraying speed and the membrane moving speed of the system to enable each 1 cm-length membrane band to be sprayed with 1-3 mul of the solutions of the C line, the solutions of the T1 line and the solutions of the T2 line, arranging the three lines on the nitrocellulose membrane in sequence of the T1 line, the T2 line and the C line from the sample adding end, putting the sprayed membrane into a vacuum pump, vacuumizing and drying to obtain the nitrocellulose membrane sequentially provided with the first test line, the second test line and the control line, and reserving the nitrocellulose membrane.
119. Film pasting: and sequentially attaching the prepared sample adding gasket, the glass cellulose membrane, the nitrocellulose membrane and the water absorption gasket on the rubber plate from top to bottom. And preparing a reagent large plate.
1110. Cutting: the reagent large plate is longitudinally cut into test strips with the width of 3-5mm by a cutter, and each test strip is 1 part.
1111. Assembling: and correspondingly installing each 1 person of test paper strips into each 1 plastic card to obtain the reagent card.
12. The chlamydia trachomatis antigen was detected using the chlamydia trachomatis detection reagent card provided in this example.
121. And (5) making a calibration curve.
Chlamydia trachomatis antigen solutions at concentrations of 0, 20IFU/ml, 50IFU/ml, 200IFU/ml, 500IFU/ml, and 1000IFU/ml were dropped onto the sample addition pad, 5 replicates were set for each concentration (the average of 5 replicates for the test result), and after 10 minutes of membrane chromatography, the color intensity of T1 line and T2 line was collected using an immunoassay instrument. When the preset concentration of the chlamydia trachomatis is 0, the color brightness value of the T1 line is 0, namely the T1 value is 0, and the color brightness value of the T2 line is 100, namely the T2 value is 100; at a concentration of 1000IFU/ml, the value of T1 is 100 and the value of T2 is 1; wherein 0 to 100 is a linear transition. The immunoassay instrument calculates color brightness values of the collected T1 line and the T2 line according to preset calculation, and calculates the value of T1/T2. Calibration curves were constructed from the values of the line T1/T2, where the Y-axis is the value of T1/T2 and the X-axis is the true value of the standard.
122. The chlamydia trachomatis detection reagent card prepared in the embodiment is used for detecting a sample to be detected.
Samples to be tested with Chlamydia trachomatis antigen concentrations of 10IFU/ml, 80IFU/ml, 300IFU/ml and 800IFU/ml were prepared, and PBS buffer was used as a control. And (3) dripping the sample to be detected on the sample adding pad, setting 5 repetitions for each sample (the detection result is an average value of the 5 repetitions), after 10 minutes of film chromatography, comparing a T1/T2 value obtained during sample detection with a standard curve to obtain a detection value, and comparing the detection value with an actual value to obtain an accuracy influence deviation value. The data obtained for the content of the detected Chlamydia trachomatis antigens in samples 1 to 4 were 11IFU/ml, 78IFU/ml, 308IFU/ml and 809IFU/ml, respectively, and no Chlamydia trachomatis antigen was detected in the blank control.
The result shows that the accuracy influence deviation value of the antigen for detecting the chlamydia trachomatis antigen provided by the invention is less than or equal to 10 percent, and the chlamydia trachomatis antigen with the concentration as low as 10IFU/ml can be accurately detected.
Example 2
21. And (3) preparing a chlamydia trachomatis detection reagent card.
The specific preparation method is described with reference to step 111-1111 of example 1, wherein the difference is that the formula of the first pretreatment solution in this example is as follows: 1.75g/L of arginine, 1.5g/L of potassium hydrogen phthalate, 0.3g/L of sodium hydroxide, 2.5g/L of citric acid and water as a solvent, wherein the pH value is 6.0. The second pretreatment liquid formula is as follows: 2.0g/L of asparagine, 0.7g/L of disodium hydrogen phosphate, 3.5g/L of rhamnose, 3.0g/L of glycine and water as a solvent, wherein the pH value is 8.0.
22. The chlamydia trachomatis detection reagent card provided in the embodiment is used for detecting chlamydia trachomatis antigen.
The detection process refers to steps 121 and 122 in embodiment 1. The detection results were 9IFU/ml, 79IFU/ml, 306IFU/ml and 807IFU/ml, respectively, and no Chlamydia trachomatis antigen was detected in the blank control.
The result shows that the accuracy influence deviation value of the antigen for detecting the chlamydia trachomatis antigen provided by the invention is less than or equal to 10 percent, and the chlamydia trachomatis antigen with the concentration as low as 10IFU/ml can be accurately detected.
Example 3
31. And (3) preparing a chlamydia trachomatis detection reagent card.
The specific preparation method is described with reference to step 111-1111 of example 1, wherein the difference is that the formula of the first pretreatment solution in this example is as follows: 2.0g/L of arginine, 1.35g/L of potassium hydrogen phthalate, 0.4g/L of sodium hydroxide, 2.25g/L of citric acid and water as a solvent, wherein the pH value is 6.3. The second pretreatment liquid formula is as follows: 2.25g/L of asparagine, 0.6g/L of disodium hydrogen phosphate, 3g/L of rhamnose, 3.25g/L of glycine and water as a solvent, wherein the pH value is 7.8.
32. The chlamydia trachomatis detection reagent card provided in the embodiment is used for detecting chlamydia trachomatis antigen.
The detection process refers to steps 121 and 122 in embodiment 1. The detection results were 10IFU/ml, 82IFU/ml, 298IFU/ml and 795IFU/ml, respectively, and no Chlamydia trachomatis antigen was detected in the blank control.
The result shows that the accuracy influence deviation value of the antigen for detecting the chlamydia trachomatis antigen provided by the invention is less than or equal to 10 percent, and the chlamydia trachomatis antigen with the concentration as low as 10IFU/ml can be accurately detected.
Comparative example 1
41. The preparation method of the reagent card for detecting chlamydia trachomatis comprises the following steps:
411. preparation of a mixed solution of latex particle-first anti-chlamydia trachomatis antibody and latex particle-test antigen:
preparation of a mixed solution of latex particle-first anti-chlamydia trachomatis antibody and latex particle-test antigen:
adding the required volume of the MOMP monoclonal antibody and the carboxylated red polystyrene latex particles into 0.05M PBS (phosphate buffer solution) with a preset volume, performing ultrasonic treatment, centrifuging and other operation steps to obtain a latex particle-first anti-chlamydia trachomatis antibody solution, diluting, and measuring the light absorption value of the suspension at 500nm by using a spectrophotometer to obtain the latex particle-first anti-chlamydia trachomatis antibody solution. Adding the required volume of rabbit IgG and carboxylated red polystyrene latex particles into 0.05M PBS (phosphate buffer solution) with a preset volume, performing ultrasonic treatment, centrifuging and other operation steps to obtain a latex particle-test antigen solution, diluting the latex particle-test antigen solution, and measuring the light absorption value of the suspension at 500nm by using a spectrophotometer to obtain the latex particle-test antigen solution. Mixing the prepared latex particle-first anti-chlamydia trachomatis antibody solution and the latex particle-test antigen solution, and storing at 2-8 ℃.
412. Diluting the mixed solution obtained in the step 411 by PBS (phosphate buffer solution) with the pH value of 6.8-7.2 and the concentration of 0.01-0.05M until the OD720 is 2.0-4.0, spraying the obtained solution onto a glass cellulose membrane, wherein the spraying amount is 2-5mg/ml, and drying at 35-45 ℃ to obtain the glass cellulose membrane containing latex particles, namely the first anti-chlamydia trachomatis antibody and the latex particles, namely the test antigen.
413. C, preparation of line solution: using PBS (0.01-0.05M, pH6.8-7.2) to prepare goat anti-rabbit IgG solution, wherein the final concentration of the solution is 1.0-2.0 mg/ml.
414. Preparing a T line solution: and (3) preparing a second anti-chlamydia trachomatis antibody solution by using PBS (phosphate buffer solution) with the pH value of 0.01-0.05M and the pH value of 6.8-7.2, wherein the LPS monoclonal antibody is used as the second anti-chlamydia trachomatis antibody, and the final concentration of the solution is 1.0-2.0 mg/ml.
415. Dot C, T lines on nitrocellulose membrane: the microalbumin membrane system was cleaned with 0.01M phosphate buffer pH 7.2. And (3) adjusting parameters of the micro-protein spot membrane system, connecting an inlet pipeline and an outlet pipeline, and respectively putting the C, T pipelines into C, T-line solution. The spraying speed and the film running speed of the system were adjusted so that 1 to 3. mu.l of C, T line solution could be sprayed per 1cm length of film tape. And (4) putting the sprayed film into a vacuum pump, vacuumizing and drying for later use.
416. Film pasting: and sequentially attaching the prepared sample adding gasket, the glass cellulose membrane, the nitrocellulose membrane and the water absorption gasket on the rubber plate from top to bottom. And preparing a reagent large plate.
417. Cutting: the reagent large plate is longitudinally cut into test strips with the width of 3-5mm by a cutter, and each test strip is 1 part.
418. Assembling: and correspondingly installing each 1 person of test paper strips into each 1 plastic card to obtain the reagent card.
42. The invention relates to a chlamydia trachomatis detection reagent card and a detection effect of the chlamydia trachomatis detection reagent card.
421. The chlamydia trachomatis detection reagent card provided by the embodiment of the invention is used for detecting chlamydia trachomatis antigen.
4211. And (5) making a calibration curve.
Chlamydia trachomatis antigen solutions at concentrations of 0, 20IFU/ml, 50IFU/ml, 200IFU/ml, 500IFU/ml, and 1000IFU/ml were dropped onto the sample addition pad, 5 replicates were set for each concentration (the detection result was averaged over 5 replicates), and after 10 minutes of membrane chromatography, T-line color brightness was collected using an immunoassay instrument. When the concentration of the chlamydia trachomatis is preset to be 0, the color brightness value of the T line is 0, namely the T1 value is 0; the T value is 100 when the concentration of the chlamydia trachomatis is 1000 IFU/ml; wherein 0 to 100 is a linear transition. And the immunoassay instrument calculates the acquired T line color brightness value according to the preset calculation and calculates the T value. And establishing a calibration curve according to the value of the T line, wherein the Y axis is the T1 value, and the X axis is the true value of the standard product.
4212. The invention relates to a detection result of a chlamydia trachomatis detection reagent card.
Samples to be tested with Chlamydia trachomatis antigen concentrations of 10IFU/ml, 80IFU/ml, 300IFU/ml and 800IFU/ml were prepared, and PBS buffer was used as a control. Dropping a sample to be detected on the sample adding gasket, setting 5 repetitions for each sample (the detection result is an average value of the 5 repetitions), after 10 minutes of film chromatography, comparing a T value obtained when the sample is detected with a standard curve to obtain a detection value, and comparing the detection value with an actual value to obtain an accuracy influence deviation value.
The results showed that no Chlamydia trachomatis antigen was detected from the concentrations of 10IFU/ml, 80IFU/ml and the blank control. And the detection results of the samples to be detected with the actual concentrations of 300IFU/ml and 800IFU/ml are 248IFU/ml and 903IFU/ml respectively.
In conclusion, the detection kit provided by the invention has good sensitivity and accuracy, effectively overcomes various defects in the prior art, and has high industrial utilization value.
The foregoing embodiments are merely illustrative of the principles and utilities of the present invention and are not intended to limit the invention. Any person skilled in the art can modify or change the above-mentioned embodiments without departing from the spirit and scope of the present invention. Accordingly, it is intended that all equivalent modifications or changes which can be made by those skilled in the art without departing from the spirit and technical spirit of the present invention be covered by the claims of the present invention.
Claims (10)
1. A reagent card for detecting chlamydia trachomatis is, which is characterized by comprising a sample adding gasket, a glass cellulose membrane, a nitrocellulose membrane and a water absorption gasket which are arranged in sequence; wherein,
the glass cellulose membrane contains latex particles, a first anti-chlamydia trachomatis antibody and latex particles, a test antigen;
the nitrocellulose membrane is sequentially provided with a first test line, a second test line and a control line;
the first test line is coated with a second anti-chlamydia trachomatis antibody;
the second test line is coated with a chlamydia trachomatis antigen;
the control line is coated with an antibody to the test antigen.
2. The Chlamydia trachomatis detection reagent card of claim 1, wherein the test antigen is rabbit IgG; the antibody of the test antigen is goat anti-rabbit IgG.
3. The Chlamydia trachomatis detection reagent card of claim 1, wherein the first anti-Chlamydia trachomatis antibody and/or the second anti-Chlamydia trachomatis antibody is a monoclonal antibody.
4. The Chlamydia trachomatis detection reagent card of claim 1, wherein the latex particles in the latex particle-first anti-Chlamydia trachomatis antibody and the first Chlamydia trachomatis antibody are linked by chemical coupling, and/or the latex particles in the latex particle-test antigen and the test antigen are linked by chemical coupling.
5. The method for preparing a reagent card for detecting chlamydia trachomatis according to any one of claims 1 to 4, comprising the steps of:
1) spraying a mixed solution of latex particles, a first anti-chlamydia trachomatis antibody and latex particles, and a test antigen on a glass cellulose membrane;
2) carrying out first pretreatment on a nitrocellulose membrane corresponding to a T1 line to be spotted by using a first pretreatment solution, and spotting a second anti-chlamydia trachomatis antibody solution on the nitrocellulose membrane subjected to the first pretreatment;
3) performing second pretreatment on the nitrocellulose membrane corresponding to the T2 line to be spotted by using a second pretreatment solution, and spotting a chlamydia trachomatis antigen solution on the nitrocellulose membrane subjected to the second pretreatment;
4) and spraying an antibody solution of the test antigen on the nitrocellulose membrane at a preset position.
6. The method of claim 5, further comprising any one or more of the following features: the first pretreatment solution is an aqueous solution containing 1.5-2g/L arginine, 1.2-1.5g/L potassium hydrogen phthalate, 0.3-0.5g/L sodium hydroxide and 2-2.5g/L citric acid; the second pretreatment solution is an aqueous solution containing 2-2.5g/L of asparagine, 0.5-0.7g/L of disodium hydrogen phosphate, 3-4g/L of rhamnose and 3-3.5g/L of glycine.
7. Use of a chlamydia trachomatis detection reagent card according to any one of claims 1 to 4 in the preparation of a chlamydia trachomatis detection kit.
8. The use according to claim 7, in particular for detecting chlamydia trachomatis antigen in a sample using the chlamydia trachomatis detection kit.
9. Use according to claim 8, characterized in that it comprises in particular:
the ratio of the value of the first test line to the value of the second test line and/or the ratio of the value of the first test line to the value of the control line is used for obtaining the content of the chlamydia trachomatis; wherein,
the value of the first test line is obtained from the color brightness exhibited by the latex particles enriched in the first test line, the value of the second test line is obtained from the color brightness exhibited by the latex particles enriched in the second test line, and the value of the control line is obtained from the color brightness exhibited by the latex particles enriched in the control line.
10. A Chlamydia trachomatis detection kit comprising the Chlamydia trachomatis detection reagent card according to any one of claims 1 to 4.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711057573.8A CN107884574A (en) | 2017-11-01 | 2017-11-01 | Chlamydia trachomatis detection reagent card, kit and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711057573.8A CN107884574A (en) | 2017-11-01 | 2017-11-01 | Chlamydia trachomatis detection reagent card, kit and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107884574A true CN107884574A (en) | 2018-04-06 |
Family
ID=61783350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711057573.8A Pending CN107884574A (en) | 2017-11-01 | 2017-11-01 | Chlamydia trachomatis detection reagent card, kit and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107884574A (en) |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0987551A2 (en) * | 1998-07-27 | 2000-03-22 | Bayer Corporation | Method for the determination of analyte concentration in a lateral flow sandwich immunoassay exhibiting high-dose hook effect |
| CN1425921A (en) * | 2001-12-11 | 2003-06-25 | 李克生 | Detection method for trachoma chlamydia antigen and its quick detection reagent kit and its preparing method |
| WO2007027231A1 (en) * | 2005-08-31 | 2007-03-08 | Kimberly-Clark Worldwide, Inc. | Diagnostic test kits with improved detection accuracy |
| CN101326440A (en) * | 2005-04-29 | 2008-12-17 | 金伯利-克拉克环球有限公司 | Assay devices having detection capabilities within the hook effect region |
| CN101661037A (en) * | 2009-09-10 | 2010-03-03 | 杭州艾力康医药科技有限公司 | Spittle rapid detection strip for chlamydia trachomatis antibody |
| CN102375056A (en) * | 2010-08-27 | 2012-03-14 | 烟台赛尔斯生物技术有限公司 | Immobilized bio-macromolecular stabilizer as well as preparation method and application thereof |
| CN102411055A (en) * | 2011-08-02 | 2012-04-11 | 中国人民解放军第三军医大学 | Nano gold test paper for detecting major outer membrane protein antigen of chlamydia trachomatis and preparation method and application thereof |
| CN202814988U (en) * | 2012-08-23 | 2013-03-20 | 南京基蛋生物科技有限公司 | Full scale high-sensitivity C-reaction protein colloidal gold test paper strip |
| CN105785038A (en) * | 2016-03-31 | 2016-07-20 | 广州市微米生物科技有限公司 | Double detection line SAA (Serum amyloid A protein) immunofluorescence chromatography quantitative detection reagent and preparation method thereof |
| CN106053794A (en) * | 2016-06-30 | 2016-10-26 | 厦门宝太生物科技有限公司 | Reagent card for accurately detecting test object, kit and application |
-
2017
- 2017-11-01 CN CN201711057573.8A patent/CN107884574A/en active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0987551A2 (en) * | 1998-07-27 | 2000-03-22 | Bayer Corporation | Method for the determination of analyte concentration in a lateral flow sandwich immunoassay exhibiting high-dose hook effect |
| CN1425921A (en) * | 2001-12-11 | 2003-06-25 | 李克生 | Detection method for trachoma chlamydia antigen and its quick detection reagent kit and its preparing method |
| CN101326440A (en) * | 2005-04-29 | 2008-12-17 | 金伯利-克拉克环球有限公司 | Assay devices having detection capabilities within the hook effect region |
| WO2007027231A1 (en) * | 2005-08-31 | 2007-03-08 | Kimberly-Clark Worldwide, Inc. | Diagnostic test kits with improved detection accuracy |
| CN101661037A (en) * | 2009-09-10 | 2010-03-03 | 杭州艾力康医药科技有限公司 | Spittle rapid detection strip for chlamydia trachomatis antibody |
| CN102375056A (en) * | 2010-08-27 | 2012-03-14 | 烟台赛尔斯生物技术有限公司 | Immobilized bio-macromolecular stabilizer as well as preparation method and application thereof |
| CN102411055A (en) * | 2011-08-02 | 2012-04-11 | 中国人民解放军第三军医大学 | Nano gold test paper for detecting major outer membrane protein antigen of chlamydia trachomatis and preparation method and application thereof |
| CN202814988U (en) * | 2012-08-23 | 2013-03-20 | 南京基蛋生物科技有限公司 | Full scale high-sensitivity C-reaction protein colloidal gold test paper strip |
| CN105785038A (en) * | 2016-03-31 | 2016-07-20 | 广州市微米生物科技有限公司 | Double detection line SAA (Serum amyloid A protein) immunofluorescence chromatography quantitative detection reagent and preparation method thereof |
| CN106053794A (en) * | 2016-06-30 | 2016-10-26 | 厦门宝太生物科技有限公司 | Reagent card for accurately detecting test object, kit and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2063269B1 (en) | Chromatography apparatus for detecting Staphylococcus aureus | |
| JP5367583B2 (en) | Immunoassay apparatus and immunoassay method | |
| CA1202236A (en) | Immunoassay methods employing patterns for the detection of soluble and cell surface antigens | |
| CA2048694A1 (en) | Assay method using surface plasmon resonance spectrometry | |
| JP2020526742A (en) | Sandwich assay using the decreasing signal portion of the dose-response curve to measure the analyte, such as a high-concentration assay | |
| CN115420892B (en) | Preparation method of fluorescence immunochromatographic test strip for combined detection of IgG type anticardiolipin antibody and IgM type anticardiolipin antibody | |
| CN105842451A (en) | Method for detecting DNMT1 on basis of quantum dot fluorescence immunoassay | |
| CN107884584A (en) | Rotavirus detection reagent card, kit and application thereof | |
| CN103954753A (en) | Quantitative determination method of immune chromatography test strip | |
| CN107907681A (en) | Adenovirus detection reagent card, kit and application thereof | |
| CN105353116A (en) | Method for immunoassay based on hydrogen peroxide test strip and applications | |
| CN107884574A (en) | Chlamydia trachomatis detection reagent card, kit and application thereof | |
| CN111239404B (en) | Detection kit capable of simultaneously detecting retinol binding protein in urine sample and serum sample | |
| JP2001021564A (en) | Dry analysis method and dry analytical element | |
| JP7619129B2 (en) | Method for determining vitamin A in whole blood | |
| US20140011190A1 (en) | Method for performing a rapid test | |
| CN107656045A (en) | Procalcitonin near-infrared fluorescent detection reagent card, kit and application thereof | |
| CN107884575A (en) | Amino terminal-pro brain natriuretic peptide detection reagent card, kit and application thereof | |
| CN115980331B (en) | Kit for detecting heparin binding protein | |
| CN111239411A (en) | Immunodetection kit for mycoplasma pneumoniae antibody IgG, preparation method and use method thereof | |
| CN107941742A (en) | β human chorionic gonadotrophin near-infrared fluorescent detection reagents card, kit and application thereof | |
| CN107907678A (en) | D dimer quantum dot fluorescence detection reagents card, kit and application thereof | |
| JP3496684B2 (en) | Colorimetric analysis using colloidal gold particles | |
| CN119355259A (en) | A colloidal gold immunochromatographic semi-quantitative test strip and detection method | |
| CN119667149A (en) | A red modified microsphere immunochromatographic test strip for detecting ochratoxin A in wine and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180406 |
|
| RJ01 | Rejection of invention patent application after publication |